Nidhi Sofat, Fiona E Watt, Ai Lyn Tan
doi : 10.1093/rheumatology/keab263
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3487–3489
Shuayb Elkhalifa, Hector Chinoy
doi : 10.1093/rheumatology/keab366
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3490–3491
Federica Bello
doi : 10.1093/rheumatology/keab368
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3492–3493
Riemer H J A Slart, Andor W J M Glaudemans, Elisabeth Brouwer, Kornelis S M van der Geest
doi : 10.1093/rheumatology/keab375
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3494–3495
Jack Arnold, Kevin Winthrop, Paul Emery
doi : 10.1093/rheumatology/keab223
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3496–3502
The coronavirus disease 2019 (COVID-19) vaccination will be the largest vaccination programme in the history of the NHS. Patients on immunosuppressive therapy will be among the earliest to be vaccinated. Some evidence indicates immunosuppressive therapy inhibits humoral response to the influenza, pneumococcal and hepatitis B vaccines. The degree to which this will translate to impaired COVID-19 vaccine responses is unclear. Other evidence suggests withholding MTX for 2 weeks post-vaccination may improve responses. Rituximab has been shown to impair humoral responses for 6?months or longer post-administration. Decisions on withholding or interrupting immunosuppressive therapy around COVID-19 vaccination will need to be made prior to the availability of data on specific COVID-19 vaccine response in these patients. With this in mind, this article outlines the existing data on the effect of antirheumatic therapy on vaccine responses in patients with inflammatory arthritis and formulates a possible pragmatic management strategy for COVID-19 vaccination.
Saba Asam, Georgiana Neag, Onorina Berardicurti, David Gardner, Francesca Barone
doi : 10.1093/rheumatology/kez050
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3503–3512
Primary SS (pSS) is a chronic autoimmune condition characterized by infiltration of the exocrine glands and systemic B cell hyperactivation. This glandular infiltration is associated with loss of glandular function, with pSS patients primarily presenting with severe dryness of the eyes and mouth. Within the affected glands, the infiltrating lymphocytes are organized in tertiary lymphoid structures. Tertiary lymphoid structures subvert normal tissue architecture and impact on organ function, by promoting the activation and maintenance of autoreactive lymphocytes. This review summarizes the current knowledge about the role of stromal cells (including endothelium, epithelium, nerves and fibroblasts) in the pathogenesis of pSS, in particular the interactions taking place between stromal cells and infiltrating lymphocytes. We will provide evidences pointing towards the driving role of stromal cells in the orchestration of the local inflammatory milieu, thus highlighting the need for therapies aimed at targeting this compartment alongside classical immunosuppression in pSS.
Gaetane Nocturne, Elena Pontarini, Michele Bombardieri, Xavier Mariette
doi : 10.1093/rheumatology/kez052
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3513–3521
Lymphoma development is the most serious complication of SS and the main factor impacting on mortality rate in patients with this condition. Lymphomas in SS are most commonly extranodal non-Hodgkin B-cell lymphomas of the mucosa-associated lymphoid tissue and frequently arise in salivary glands that are the target of a chronic inflammatory autoimmune process. Extensive work on lymphomagenesis in SS has established that the progression towards B-cell lymphoma is a multistep process related to local chronic antigenic stimulation of B cells. These neoplastic B cells in SS frequently derived from autoreactive clones, most commonly RF-producing B cells, which undergo uncontrolled proliferation and malignant escape. In this review, we highlight the most important recent findings that have enhanced our understanding of lymphoma development in SS, with particular reference to the close link between autoimmunity and lymphomagenesis. We also discuss how the identification of key factors involved in B-cell malignancies may impact on our ability to identify at early stages patients at increased risk of lymphoma with potential significant repercussions for the clinical management of SS patients. Finally, we identified the most promising areas of current and further research with the potential to provide novel basic and translational discoveries in the field. The questions of finding new biomarkers, developing a validated score for predicting lymphoma occurrence and assessing if a better control of disease activity will decrease the risk of lymphoma in primary SS will be the enthralling questions of the next few years.
Valerie Devauchelle-Pensec, Alen Zabotti, Guillermo Carvajal-Alegria, Nenad Filipovic, Sandrine Jousse-Joulin, Salvatore De Vita
doi : 10.1093/rheumatology/kez079
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3522–3527
Salivary gland ultrasonography (SGUS) has an established role in detecting typical structural gland abnormalities in primary Sj?gren’s Syndrome (pSS). SGUS might be included in pSS classification and could be used as a prognostic and follow-up biomarker, but for this purpose additional efforts, new techniques and larger cohort studies are needed. HarmonicSS, an ongoing Horizon, EU-supported project in pSS, will apply artificial intelligence to SGUS in pSS. Many questions are still unresolved and challenging, but data collected up to now underscore the concept that SGUS will be an important tool for the study of pSS in the near future.
Raphaèle Seror, Saaeha Rauz, Marjolaine Gosset, Simon J Bowman
doi : 10.1093/rheumatology/kez201
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3528–3539
In primary SS (pSS), clinical features in SS can be divided into two facets: the patient perceived manifestations such as dryness, pain and fatigue, and the systemic manifestations. In the past decades, with efforts made by an international collaboration, consensual clinical indexes were developed for assessing both facets: one patient reported outcome, the EULAR SS Patients Reported Index (ESSPRI), and one activity index for systemic manifestations, the EULAR SS Disease Activity Index (ESSDAI). In addition, objective measures were developed to quantify the importance and consequence of ocular and oral dryness, few being specific of pSS. Work is ongoing to develop indexes combining all these approaches. Recent changes in the assessment of pSS patients, and the emergence of new targeted therapies, have put a greater emphasis on the design of clinical trials in pSS, and led for the first time to a positive randomized clinical trial.
Hema Chaplin, Lewis Carpenter, Anni Raz, Elena Nikiphorou, Heidi Lempp, Sam Norton
doi : 10.1093/rheumatology/keab237
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3540–3552
To identify how refractory disease (or relevant terminology variations) in RA and polyarticular JIA (polyJIA) is defined and establish the key components of such definitions.
Sara Monti, Paolo Delvino, Mattia Riboli, Chiara Rebuffi, Blerina Xoxi, Annalisa De Silvestri, Carlomaurizio Montecucco
doi : 10.1093/rheumatology/keab267
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3553–3564
To assess available evidence from randomized controlled trials (RCTs) and observational studies including a control group regarding the role of trimethoprim/sulfametoxazole (TMP/SMX) in reducing the relapse rate in patients with granulomatosis with polyangiitis (GPA) and the risk of infections in patients with ANCA-associated vasculitis (AAV).
Ian Giles, Alexander Allen, Amy Crossley, Julia Flint, Margreta Frishman, Mary Gayed, Munther Kamashta, Louise Moore, Sonia Panchal, Madeline Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Senvar, Sofia Tosounidou, Maud van de Venne, Louise Warburton, David Wiliams, Chee-Seng Yee, Caroline Gordon
doi : 10.1093/rheumatology/keab334
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3565–3569
Gyanendra Pokharel, Rob Deardon, Sindhu R Johnson, George Tomlinson, Pauline M Hull, Glen S Hazlewood
doi : 10.1093/rheumatology/keaa803
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3570–3578
To quantify rheumatologists’ beliefs about the effectiveness of triple therapy (MTX + HCQ + SSZ) and other commonly used initial treatments for RA.
Linda Rossi-Semerano, Sylvain Breton, Luca Semerano, Marouane Boubaya, Haykanush Ohanyan, Marie Bossert, Sorina Boiu, Emmanuel Chatelus, Géraldine Durand, Sylvie Jean, Laurence Goumy, Anne Mathiot, Gaël Mouterde, Frédérique Nugues, Ahmed Ould Hennia, Bénédicte Rey, Annette Von Scheven, Laetitia Sparsa, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin
doi : 10.1093/rheumatology/keaa804
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3579–3587
To evaluate the reliability of the OMERACT paediatric ultrasound (US) synovitis definitions and scoring system in JIA.
Eefje M van Helvoort, Diana Hodgins, Simon C Mastbergen, Anne Karien Marijnissen, Hans Guehring, Marieke Loef, Margreet Kloppenburg, Francisco Blanco, Ida K Haugen, Francis Berenbaum, Floris P J G Lafeber, Paco M J Welsing
doi : 10.1093/rheumatology/keaa809
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3588–3597
To assess underlying domains measured by GaitSmartTMparameters and whether these are additional to established OA markers including patient reported outcome measures (PROMs) and radiographic parameters, and to evaluate if GaitSmart analysis is related to the presence and severity of radiographic knee OA.
Jérôme Avouac, Muriel Elhai, Marine Forien, Jérémie Sellam, Florent Eymard, Anna Molto, Frédéric Banal, Joël Damiano, Philippe Dieudé, Etienne Larger, Yannick Allanore
doi : 10.1093/rheumatology/keaa810
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3598–3606
To study the profile of type-2 diabetes (T2D) in patients with RA or OA.
Stephanie R Harrison, Agata N Burska, Paul Emery, Helena Marzo-Ortega, Frederique Ponchel
doi : 10.1093/rheumatology/keaa817
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3607–3616
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. TNF inhibitor (TNFi) drugs are recommended for patients not responding to NSAIDs; however, there is a significant need for biomarkers of response. IFN-regulated genes (IRGs) and other cytokines/chemokines are linked to autoimmune diseases and have been associated with treatment response. Our objective was to explore whether IRGs and cytokines/chemokines can be associated with response to TNFiagents in AS.
N Luurssen-Masurel, A E A M Weel, G H Koc, J M W Hazes, P H P de Jong, for the tREACH group investigators
doi : 10.1093/rheumatology/keaa820
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3617–3627
Management of early arthritis is based upon early recognition of individuals at high risk of developing persistent arthritis. Therefore, this study investigates whether the number of risk factors for persistent disease or treatment determines the clinical course of early arthritis by comparing the chance at (sustained) DMARD-free remission ((S)DFR) after 2?years follow-up.
Jine Lu, Zhiyao Bai, Yunqing Chen, Yingxu Li, Min Tang, Ning Wang, Xingcheng Zhu, Hongbin Dai, Weiya Zhang
doi : 10.1093/rheumatology/keaa822
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3628–3634
Weight reduction may reduce serum uric acid (SUA). This study aimed to examine the changes of SUA before and after bariatric surgery in patients with obesity with or without hyperuricaemia and gout.
Ulf Lindstr?m, Bente Glintborg, Daniela Di Giuseppe, Tanja Schj?dt J?rgensen, Bjorn Gudbjornsson, Kathrine Lederballe Gr?n, Sella Aarrestad Provan, Brigitte Michelsen, Merete Lund Hetland, Johan K Wallman, Dan Nordstr?m, Nina Trokovic, Thorvardur Jon Love, Niels Steen Krogh, Johan Askling, Lennart T H Jacobsson, Lars Erik Kristensen
doi : 10.1093/rheumatology/keaa825
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3635–3645
To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.
Nina M van Leeuwen, Jacopo Ciaffi, Sophie I E Liem, Tom W J Huizinga, Jeska K de Vries-Bouwstra
doi : 10.1093/rheumatology/keaa827
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3646–3655
In SSc patients, disease specific determinants that influence health-related quality of life (HRQoL) over time have not been described. We aim to, in patients with SSc, (i) evaluate if and how HRQoL changes over time, and (ii) assess how different SSc domains and functional impairments contribute to changes in HRQoL over time.
Karin Hellgren, Christine Ballegaard, Bénédicte Delcoigne, René Cordtz, Dan Nordstr?m, Kalle Aaltonen, Bjorn Gudbjornsson, Thorvardur Jon Love, Sella Aarrestad Provan, Joe Sexton, Kristian Zobbe, Lars Erik Kristensen, Johan Askling, Lene Dreyer
doi : 10.1093/rheumatology/keaa828
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3656–3668
To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA).
Takamitsu Makino, Hironobu Ihn, Motoo Nakagawa, Misugi Urano, Ryuhei Okuyama, Norito Katoh, Chiharu Tateishi, Koji Masuda, Eisaku Ogawa, Emi Nishida, Shohei Nishimoto, Kenzo Muramoto, Daisuke Tsuruta, Akimichi Morita
doi : 10.1093/rheumatology/keaa829
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3669–3678
PsA is characterized by enthesitis, synovitis and osseous involvement in the peripheral and axial joints. Few studies have examined axial involvement in PsA using imaging techniques. Here we examined axial involvement in PsA patients using MRI. In addition, we determined the efficacy of 24?week adalimumab treatment in improving the MRI findings of spondylitis and sacroiliitis.
Andrew R Melville, Md Yuzaiful Md Yusof, John Fitton, Leticia Garcia-Montoya, Lynda Bailey, Shouvik Dass, Paul Emery, Maya H Buch, Benazir Saleem
doi : 10.1093/rheumatology/keaa834
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3679–3688
To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with RA.
Jeffrey A Sparks, Yinzhu Jin, Soo-Kyung Cho, Seanna Vine, Rishi Desai, Tracy J Doyle, Seoyoung C Kim
doi : 10.1093/rheumatology/keaa836
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3689–3698
We aimed to investigate the prevalence, incidence and cause-specific mortality of RA-associated interstitial lung disease (RA-ILD) among older US patients with RA.
Veerle Stouten, René Westhovens, Diederik De Cock, Kristien Van der Elst, Sofia Pazmino, Delphine Bertrand, Johan Joly, Patrick Verschueren
doi : 10.1093/rheumatology/keaa841
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3699–3708
To quantify the prevalence of co-morbidities in patients with early RA and determine their prognostic value for effectiveness outcomes in a randomized trial.
Tim Y Koppert, Johannes W G Jacobs, Rinie Geenen
doi : 10.1093/rheumatology/keaa842
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3709–3715
To determine the psychological impact of the COVID-19 pandemic on people with and without an inflammatory rheumatic disease and establish whether psychological flexibility buffers this impact.
Nathalie Luurssen-Masurel, Angelique Elisabeth Adriana Maria Weel, Johanna Maria Wilhelmina Hazes, Pascal Hendrik Pieter de Jong, the tREACH group investigators
doi : 10.1093/rheumatology/keaa845
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3716–3726
To compare patient-reported outcome (PRO) domains between three arthritis phenotypes [undifferentiated arthritis (UA), autoantibody-negative RA (RA?) and autoantibody-positive RA (RA+)] at diagnosis, after 2?years and over time.
Maxim B Freidin, Maria A Stalteri, Philippa M Wells, Genevieve Lachance, Andrei-Florin Baleanu, Ruth C E Bowyer, Alexander Kurilshikov, Alexandra Zhernakova, Claire J Steves, Frances M K Williams
doi : 10.1093/rheumatology/keaa847
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3727–3737
Chronic widespread musculoskeletal pain (CWP) is a characteristic symptom of fibromyalgia, which has been shown to be associated with an altered gut microbiome. Microbiome studies to date have not examined the milder CWP phenotype specifically nor have they explored the role of raised BMI. The aim of this study was to investigate whether the microbiome is abnormal in CWP.
Camille Roubille, Amandine Coffy, Nathalie Rincheval, Maxime Dougados, René-Marc Flipo, Jean-Pierre Daurès, Bernard Combe
doi : 10.1093/rheumatology/keaa850
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3738–3746
To explore the 10-year tolerability profile of glucocorticoids (GC) use in patients with early RA.
Jennifer C Davies, Emil Carlsson, Angela Midgley, Eve M D Smith, Ian N Bruce, Michael W Beresford, Christian M Hedrich, the BILAG-BR and MRC MASTERPLANS Consortia
doi : 10.1093/rheumatology/keaa851
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3747–3759
?30% of patients with SLE develop LN. Presence and/or severity of LN are currently assessed by renal biopsy, but biomarkers in serum or urine samples may provide an avenue for non-invasive routine testing. We aimed to validate a urinary protein panel for its ability to predict active renal involvement in SLE.
Liselotte Tidblad, Helga Westerlind, Bénédicte Delcoigne, Johan Askling, Saedis Saevarsdottir
doi : 10.1093/rheumatology/keaa856
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3760–3769
Comorbidities contribute to the morbidity and mortality in RA, and are thus important to capture and treat early. In contrast to the well-studied comorbidity risks in established RA, less is known about the comorbidity pattern up until diagnosis of RA. We therefore compared whether the occurrence of defined conditions, and the overall comorbidity burden at RA diagnosis, is different from that in the general population, and if it differs between seropositive and seronegative RA.
Selcan Demir, Jessica Li, Laurence S Magder, Michelle Petri
doi : 10.1093/rheumatology/keaa857
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3770–3777
We evaluated which aPL combinations increase the risk of future thrombosis in patients with SLE.
Nadia M T Roodenrijs, Marlies C van der Goes, Paco M J Welsing, Janneke Tekstra, Floris P J G Lafeber, Johannes W G Jacobs, Jacob M van Laar
doi : 10.1093/rheumatology/keaa860
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3778–3788
Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.
Liselotte Tidblad, Helga Westerlind, Bénédicte Delcoigne, Johan Askling, Saedis Saevarsdottir
doi : 10.1093/rheumatology/keaa856
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3760–3769
Comorbidities contribute to the morbidity and mortality in RA, and are thus important to capture and treat early. In contrast to the well-studied comorbidity risks in established RA, less is known about the comorbidity pattern up until diagnosis of RA. We therefore compared whether the occurrence of defined conditions, and the overall comorbidity burden at RA diagnosis, is different from that in the general population, and if it differs between seropositive and seronegative RA.
Seza ?zen, Erdal Sag, Eldad Ben-Chetrit, Marco Gattorno, Ahmet Gül, Philip J Hashkes, Isabelle Kone-Paut, Helen J Lachmann, Elena Tsitsami, Marinka Twilt, Fabrizio de Benedetti, Jasmin B Kuemmerle-Deschner
doi : 10.1093/rheumatology/keaa863
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3799–3808
Colchicine is the main treatment for FMF. Although a number of individuals with FMF are intolerant/resistant to colchicine, there is no standard definition of colchicine resistance/intolerance. We developed a set of evidence-based core statements defining colchicine resistance/intolerance in patients with FMF that may serve as a guide for clinicians and health authorities.
Nadia M T Roodenrijs, Marlies C van der Goes, Paco M J Welsing, Janneke Tekstra, Floris P J G Lafeber, Johannes W G Jacobs, Jacob M van Laar
doi : 10.1093/rheumatology/keaa860
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3778–3788
Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.
Suzanne C Li, Kathryn S Torok, Sarah S Ishaq, Mary Buckley, Barbara Edelheit, Kaleo C Ede, Christopher Liu, C Egla Rabinovich
doi : 10.1093/rheumatology/keaa873
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3817–3825
To evaluate the safety and efficacy of abatacept treatment for refractory juvenile localized scleroderma (jLS) in a retrospective study.
Alicia Garc?a-Dorta, Juan Carlos Quevedo-Abeledo, ??igo Rua-Figueroa, Antonia M de Vera-Gonz?lez, Alejandra Gonz?lez-Delgado, Lilian Medina-Vega, Agust?n F Gonz?lez-Rivero, Felix Francisco-Hern?ndez, Miguel A Gonz?lez-Gay, Iv?n Ferraz-Amaro
doi : 10.1093/rheumatology/keaa874
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3826–3833
To investigate how markers of beta-cell secretion (proinsulin-processing metabolites) are expressed in SLE patients and their potential relation to features associated with the disease such as activity or damage.
Simon Krabbe, Kathrine L Gr?n, Bente Glintborg, Mette N?rgaard, Frank Mehnert, Dorte E Jarb?l, Mikkel ?stergaard, Merete L Hetland
doi : 10.1093/rheumatology/keaa876
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3834–3844
Serious infection is a concern for patients with inflammatory joint diseases treated with biological drugs (bDMARDs). The objectives were to compare risk of serious infection, defined as infection leading to hospitalization, in patients initiating bDMARD treatment with that in the general population and, second, to develop a simple clinical prediction model and to obtain risk estimates for individual patients.
Eduardo Mart?n-Nares, Gabriela Hernandez-Molina
doi : 10.1093/rheumatology/keab124
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3845–3850
To evaluate the prevalence and meaning of antineutrophil cytoplasmic antibodies (ANCA) positivity in a cohort of IgG4-related disease (IgG4-RD).
Verena Sch?nau, Jessica Roth, Koray Tascilar, Giulia Corte, Bernhard Manger, Juergen Rech, Daniela Schmidt, Alexander Cavallaro, Michael Uder, Filippo Crescentini, Luigi Boiardi, Massimiliano Casali, Lucia Spaggiari, Elena Galli, Torsten Kuwert, Annibale Versari, Carlo Salvarani, Georg Schett, Francesco Muratore
doi : 10.1093/rheumatology/keab332
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3851–3861
Efficacy evaluation of GCA treatment is primarily based on non-specific symptoms and laboratory markers. We aimed to assess the change in vascular inflammation in patients with large vessel (LV)-GCA under different treatments using [18F]FDG PET/CT.
Michael Berks, Graham Dinsdale, Elizabeth Marjanovic, Andrea Murray, Chris Taylor, Ariane L Herrick
doi : 10.1093/rheumatology/keaa723
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3862–3867
Universal serial bus (USB) microscopy (capillaroscopy) could provide all rheumatologists with an easy-to-use, low-cost tool to examine the nailfold capillaries to facilitate early diagnosis of SSc. The objectives of this pilot study were to examine the feasibility of acquiring and analysing images using USB microscopy and to compare results to videocapillaroscopy.
Francesco Morotti, Giulia Bracciolini, Roberta Caorsi, Lorella Cattaneo, Marco Gattorno, Angelo Ravelli, Enrico Felici
doi : 10.1093/rheumatology/keaa743
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3868–3871
Henoch–Sch?nlein purpura (HScP) may present in children with severe, occasionally refractory, gastrointestinal (GI) involvement. The use of corticosteroids (CSs) is commonplace in the management of the disease, but to date no standardized protocol is available and, although rare, resistance to CS therapy may be challenging to clinicians. IVIG has been proposed as an effective alternative to CSs, but to date no controlled trial has been conducted to ascertain their real efficacy. We share our personal experience of successful IVIG treatment in two cases of GI HScP, comparing it with similar experiences reported in literature.
Cleo Rogier, Fenne Wouters, Laurette van Boheemen, Dirkjan van Schaardenburg, Pascal H P de Jong, Annette H M van der Helm-van Mil
doi : 10.1093/rheumatology/keaa774
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3872–3878
According to guidelines, clinical arthritis is mandatory for diagnosing RA. However, in the absence of clinical synovitis, imaging-detected subclinical synovitis is increasingly used instead and is considered as a starting point for DMARD therapy. To search for evidence we studied the natural course of arthralgia patients with subclinical synovitis from three longitudinal cohorts and determined the frequencies of non-progression to clinically apparent inflammatory arthritis (IA) (i.e. ‘false positives’).
Line Marker, Peter Schjerling, Abigail L Mackey, Thomas Hansen, Jens Jakobsen, Michael Kj?r, Michael R Krogsgaard
doi : 10.1093/rheumatology/keaa802
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3879–3887
Primary frozen shoulder (pFS) has three phases that differ in clinical presentation. It is characterized by contracture of the joint capsule. We hypothesized that there is a general upregulation of collagens in pFS, and that this is highest in the first phase of the disease. The aims of this study were to investigate the expression of various collagens and degradation of collagens in patients with primary pFS and relate this to the three phases of the condition.
Hideto Nagai, Yohei Kirino, Hiroto Nakano, Yosuke Kunishita, Riko Henmi, Ann Marie Szymanski, Ryusuke Yoshimi, Michael J Ombrello, Hideaki Nakajima
doi : 10.1093/rheumatology/keaa814
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3888–3895
Elevation of serum IL-18 in adult-onset Still's disease (AOSD) and systemic JIA (sJIA) suggests the role of the inflammasome in these diseases. Gasdermin D is a pore-forming protein playing central roles in inflammasome-mediated inflammation, but its role in rheumatic disease is unknown. We aimed to elucidate the auto-inflammatory mechanisms in AOSD and sJIA.
Dingxian Zhu, Jianjun Qiao, Shunli Tang, Yunlei Pan, Sheng Li, Changyi Yang, Hong Fang
doi : 10.1093/rheumatology/keaa819
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3896–3903
The present study aimed to determine the correlation between serum carcinoembryonic antigen (CEA) level and the severity of interstitial lung disease (ILD) in clinically amyopathic DM (CADM) patients.
Juan Irure-Ventura, Carmen Rodr?guez, Esther Vergara-Prieto, Maria Luisa Vargas, Bibiana Quirant, Aurora Jurado, Luis Fern?ndez-Pereira, Eva Mart?nez-C?ceres, Miriam San José, Marcos L?pez-Hoyos, the GEAI and EASI groups
doi : 10.1093/rheumatology/keaa831
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3904–3912
ANA are the most extensively used test for the diagnosis of systemic autoimmune diseases. However, testing by indirect immunofluorescence assays (IIFAs) on HEp-2 cells, the gold standard test, is time-consuming and needs expertise. Thus there is a trend to replace it with other automated solid-phase assays directed against specific ANA. Nonetheless, the Hep-2 cell is an autoantigen array and ANA have been classified into 29 types, some of them with no clear association with a specificity to be detected. It is especially in these uncommon patterns where no clinical relationship is found and no antigenic specificity is detected. Here we retrospectively collected clinical data from patients with confirmed uncommon HEp-2 IIFA patterns to search for an associated clinical condition.
Xianhua Gui, Miao Ma, Jingjing Ding, ShenYun Shi, Xiaoyan Xin, Xiaohua Qiu, Yingwei Zhang, Yuying Qiu, Min Cao, Mei Huang, Mengshu Cao, Jinghong Dai, Hourong Cai, Yonglong Xiao
doi : 10.1093/rheumatology/keaa843
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3913–3922
In the present study, we aimed to assess the clinical significance of cytokeratin 19 fragment (CYFRA21-1) in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive DM-interstitial lung disease (MDA5-DM-ILD).
Sungsin Jo, Eun Jeong Won, Moon-Ju Kim, Yu Jeong Lee, So-Hee Jin, Pu-Reum Park, Ho-Chun Song, Jahae Kim, Yoo-Duk Choi, Ji-Young Kim, Seung Cheol Shim, Sung Hoon Choi, Ye-Soo Park, Tae-Hwan Kim, Tae-Jong Kim
doi : 10.1093/rheumatology/keaa846
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3923–3935
AS is a rheumatic disease characterized by chronic inflammation and bony ankylosis. This study was to evaluate whether a signal transducer and activator of transcription 3 phosphorylation inhibitor (stat3-p Inh) could treat both chronic inflammation and bone formation in AS.
Jinghui Huang, Nien Yee Kow, Hui Yin Lee, Anna-Marie Fairhurst, Anselm Mak
doi : 10.1093/rheumatology/keaa875
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3936–3944
To identify and quantify the level of CD34+CD133+CD309+ circulating angiogenic cells (CAC) and explore factors associated with the level of CAC in patients with SLE.
Yasir Suleman, Kristina E N Clark, Alice R Cole, Voon H Ong, Christopher P Denton
doi : 10.1093/rheumatology/keab273
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3945–3946
Gaia Mancuso, Tatiana Jofra, Marco Lanzillotta, , Alessandro Aiuti, Maria Pia Cicalese, Giulia di Colo, Lorenzo Dagna, , Georgia Fousteri, Emanuel Della-Torre
doi : 10.1093/rheumatology/keab344
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3947–3949
Rubén Queiro, Sabela Fern?ndez, Estefan?a Pardo
doi : 10.1093/rheumatology/keab365
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3949–3951
Rym Abida, Emily Apsley, David Isenberg
doi : 10.1093/rheumatology/keab387
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3951–3952
Ayumi Kuzume, Toshiki Terao, Daisuke Miura, Kengo Takeuchi, Kosei Matsue
doi : 10.1093/rheumatology/keaa833
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3953–3954
Shinji Izuka, Shunta Kaneko, Takuya Harada, Hidenori Sakai, Yuko Takahashi, Hiroyuki Yamashita, Hiroshi Kaneko
doi : 10.1093/rheumatology/keaa838
Rheumatology, Volume 60, Issue 8, August 2021, Page 3955
Jonathan Broner, Erik Arnaud, Sirivanh Bisiou, Agathe Artiaga, Myriam Fantone, Samia Gonzalez, Radjiv Goulabchand
doi : 10.1093/rheumatology/keaa866
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3956–3957
Furkan Ufuk, Goksel Altinisik, Ugur Karasu
doi : 10.1093/rheumatology/keaa879
Rheumatology, Volume 60, Issue 8, August 2021, Pages 3958–3959
John D Pauling, Lisa Christopher-Stine
doi : 10.1093/rheumatology/keab431
Rheumatology, Volume 60, Issue 8, August 2021, Page 3960
Tajamul H Mir, Bushra Jabeen
doi : 10.1093/rheumatology/keab002
Rheumatology, Volume 60, Issue 8, August 2021, Pages e272–e274
Jemima Albayda, Lindsey R Hayes, Lisa Christopher-Stine
doi : 10.1093/rheumatology/keab088
Rheumatology, Volume 60, Issue 8, August 2021, Pages e275–e276
Shota Okamoto, Yuya Kondo, Kimi Sato, Taihei Nishiyama, Hirofumi Toko, Mizuki Yagishita, Masahiro Yokosawa, Hiroto Tsuboi, Masaki Ieda, Isao Matsumoto
doi : 10.1093/rheumatology/keab142
Rheumatology, Volume 60, Issue 8, August 2021, Pages e277–e279
Yvonne Tan, Andrew Gough
doi : 10.1093/rheumatology/keab171
Rheumatology, Volume 60, Issue 8, August 2021, Pages e280–e281
Mary Clare McKenna, Michael Marnane, Barry J Sheane, Se?n Connolly
doi : 10.1093/rheumatology/keab186
Rheumatology, Volume 60, Issue 8, August 2021, Pages e282–e283
Claudio Galluzzo, Chiara Marvisi, Giulia Besutti, Lucia Spaggiari, Francesco Muratore, Giulia Pazzola, Gianluigi Bajocchi, Carlo Salvarani
doi : 10.1093/rheumatology/keab188
Rheumatology, Volume 60, Issue 8, August 2021, Pages e285–e287
Yvonne Tan, Svetlana Kavaklieva, Fiona Wood
doi : 10.1093/rheumatology/keab194
Rheumatology, Volume 60, Issue 8, August 2021, Pages e288–e289
Keiichiro Kadoba, Ryu Watanabe, Motomu Hashimoto, Akio Morinobu, Chikashi Terao, Hajime Yoshifuji
doi : 10.1093/rheumatology/keab184
Rheumatology, Volume 60, Issue 8, August 2021, Pages e290–e291
Maaike Heslinga, Gilles Lambert, Aurélie Thédrez, John Kastelein, Michael T Nurmohamed
doi : 10.1093/rheumatology/keab187
Rheumatology, Volume 60, Issue 8, August 2021, Pages e292–e293
Ay?e Tanatar, Hafize Emine S?nmez, Betül S?zeri, Nuray Aktay Ayaz
doi : 10.1093/rheumatology/keab205
Rheumatology, Volume 60, Issue 8, August 2021, Pages e294–e295
Mickael Essouma
doi : 10.1093/rheumatology/keab212
Rheumatology, Volume 60, Issue 8, August 2021, Page e296
C Comarmond, S Bensalha, A Lopes, F Dor, I Brocheriou, S Mouly, D Sène
doi : 10.1093/rheumatology/keab213
Rheumatology, Volume 60, Issue 8, August 2021, Pages e297–e299
Maria Maddalena Sirufo, Lia Ginaldi, Massimo De Martinis
doi : 10.1093/rheumatology/keab292
Rheumatology, Volume 60, Issue 8, August 2021, Page e300
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟